(bla VIM) and their clinical impact, microbiological, biochemical, and structural studies were
conducted. Forty-five clinically derived VIM variants engineered in a uniform background
and expressed in Escherichia coli afforded increased resistance toward all tested antibiotics;
the variants belonging to the VIM-1-like and VIM-4-like families exhibited higher MICs
toward five out of six antibiotics than did variants belonging to the widely distributed and …